NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.

Cover of Drugs and Lactation Database (LactMed)

Drugs and Lactation Database (LactMed) [Internet].

Show details

Ponatinib

Last Revision: December 21, 2020.

Estimated reading time: 1 minute

CASRN: 943319-70-8

image 135263267 in the ncbi pubchem database

Drug Levels and Effects

Summary of Use during Lactation

No information is available on the clinical use of ponatinib during breastfeeding. Because ponatinib is more than 99% bound to plasma proteins, the amount in milk is likely to be low. However, its half-life is about 24 hours and it might accumulate in the infant. National Comprehensive Cancer Network guidelines recommend avoiding breastfeeding during ponatinib therapy and the manufacturer recommends withnholding breastfeeding until 6 days following the last dose.[1]

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

Imatinib

References

1.
Deininger MW, Shah NP, Altman JK, et al. Chronic myeloid leukemia, Version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18:1385–415. [PubMed: 33022644]

Substance Identification

Substance Name

Ponatinib

CAS Registry Number

943319-70-8

Drug Class

Breast Feeding

Lactation

Antineoplastic Agents

Enzyme Inhibitors

Protein Kinase Inhibitors

Signal Transduction Inhibitors

Tyrosine Kinase Inhibitors

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Views

Related information

Similar articles in PubMed

  • Review Nilotinib[Drugs and Lactation Database (...]
    Review Nilotinib
    . Drugs and Lactation Database (LactMed). 2006
  • Review Bosutinib[Drugs and Lactation Database (...]
    Review Bosutinib
    . Drugs and Lactation Database (LactMed). 2006
  • Review Dasatinib[Drugs and Lactation Database (...]
    Review Dasatinib
    . Drugs and Lactation Database (LactMed). 2006
  • Review Nintedanib[Drugs and Lactation Database (...]
    Review Nintedanib
    . Drugs and Lactation Database (LactMed). 2006
  • Review Sorafenib[Drugs and Lactation Database (...]
    Review Sorafenib
    . Drugs and Lactation Database (LactMed). 2006
See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...